Videos

Valencia D. Thomas, MD, MHCM, discusses the current landscape for patients with non-melanoma skin cancers.

Mark A. Socinski, MD, discusses types of EGFR mutations in non–small cell lung cancer and the treatments that target these mutations.

Pierre Gholam, MD, discusses his thoughts on a phase 3 trial which evaluated camrelizumab plus rivoceranib vs sorafenib in the first-line for patients with unresectable hepatocellular carcinoma.

Robert L. Coleman, MD, and Krishnansu S. Tewari, MD, reflect on data from the GARNET clinical trial of dostarlimab in dMMR recurrent endometrial carcinoma.

Shared insight on the utilization of pembrolizumab in dMMR recurrent endometrial carcinoma in the context of the KEYNOTE-158 clinical trial.

Rupesh Kotecha, MD, discusses results of an analysis which centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

Matthew A. Ingham, MD, discusses the key takeaways from an article he co-authored regarding novel therapeutics in uterine sarcoma.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses why the number of patients with gynecologic cancer that never see a gynecologic oncologist is so high.

Closing out her discussion on the management of recurrent endometrial cancer, Ritu Salani, MD, MBA, shares clinical pearls amidst the shifting treatment paradigm.

A focused review of clinical trial data that inform the use of immune checkpoint inhibition in the setting of recurrent endometrial cancer.

An expert gynecologic oncologist shares her perspective on treatment options available to patients in the first- and second-line settings of endometrial cancer.

Opening her discussion on a patient case of recurrent endometrial cancer, Ritu Salani, MD, MBA, highlights the evolving role of molecular testing in this setting.

Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.

Matthew Anderson, MD, PhD, discusses how the results with niraparib for patients with advanced ovarian cancer impacts the use of somatic profiling in this patient population.

A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.

Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.

Bruno Bockorny, MD, explains the mechanism of action of botensilimab and its use in combination with balstilimab for ovarian cancer treatment.

Yuri E. Nikiforov, MD, PhD, discusses the approach to treating noninvasive follicular thyroid neoplasm with papillary-like nuclear features, which is now classified distinctly from thyroid cancers.

Emma Searle, discusses safety results of the MajestTEC-2 trial which combined teclistamab with daratumumab and lenalidomide in patients with multiple myeloma.

John T. Nauseef, MD, PhD, discusses an investigational prostate-specific membrane antigen targeted therapy for the treatment of metastatic castration-resistant prostate cancer.

Pierre Gholam, MD, discusses the phase 3 LEAP-002 study of lenvatinib and pembrolizumab for unresectable hepatocellular carcinoma.

Robert L. Coleman, MD, opens discussion on a second patient case and highlights critical aspects of mismatch repair deficient (dMMR) recurrent endometrial carcinoma.

Before closing out their discussion on the first patient case, key opinion leaders on endometrial carcinoma reflect on the optimal selection and sequencing of therapy in pMMR recurrent disease.

Chad Tang, MD, discusses currently available treatment options and recent research in the prostate cancer space.

John Allan, MD, provides insights on novel agents and treatment strategies currently being studied in chronic lymphocytic leukemia.

An expert hematologist-oncologist offers advice for community oncologists who are treating patients with newly diagnosed chronic lymphocytic leukemia.

An overview of assessing risk of disease recurrence, steps taken to minimize recurrence, and when to consider second-line treatment for patients with CLL.

An expert on CLL reviews recent data updates from studies of BTK inhibitors in the frontline setting.

Mathew R. Smith, MD, PhD closes the discussion by sharing clinical pearls for community oncologists and highlights unmet needs in the CRPC landscape.

Dr. Smith presents key data concerning the use of darolutamide in patients with castration-resistant CRPC, with a focus on safety and patient quality of life.